Vytorin vs. Repatha
See how Vytorin and Repatha compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Vytorin is a once-daily pill combining a statin and cholesterol absorption inhibitor, while Repatha is an injectable monoclonal antibody given every two weeks or monthly.
Both drugs lower LDL cholesterol, but only Repatha is specifically approved to reduce heart attack and stroke risk in people with existing cardiovascular disease.
Vytorin carries a risk of muscle and liver side effects tied to its statin component, while Repatha's main tradeoff is the need for regular injections.
Vytorin vs. Repatha Drug Summary
Vytorin
Vytorin combines ezetimibe and simvastatin in one tablet, blocking cholesterol absorption in the gut while reducing cholesterol production in the liver. It is FDA-approved for lowering LDL cholesterol, total cholesterol, and triglycerides in primary hyperlipidemia, as well as for homozygous familial hypercholesterolemia and homozygous sitosterolemia. It is taken as a single tablet by mouth once a day.
Repatha
Repatha is a PCSK9 inhibitor, a lab-made antibody that helps the liver clear more LDL cholesterol from the blood. It is FDA-approved to lower LDL cholesterol in adults and children 10 and older with familial hypercholesterolemia, and to reduce the risk of heart attack, stroke, and certain heart procedures in adults with existing cardiovascular disease. It is given as a subcutaneous injection every two weeks or once a month.
Vytorin vs. Repatha Side Effects
Vytorin
Repatha
Vytorin vs. Repatha Dosage
Vytorin
Repatha
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg/10 mg once daily | At the start |
| Maximum dose | 10 mg/80 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 140 mg every 2 weeks | At the start |
| Maximum dose | 420 mg every 2 weeks | If needed |
| Dose changes | 2 increases | As tolerated |
Vytorin
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg/10 mg once daily | At the start |
| Maximum dose | 10 mg/80 mg once daily | If needed |
| Dose changes | 3 increases | As tolerated |
Repatha
| STAGE | DOSE | WHEN |
| Starting dose | 140 mg every 2 weeks | At the start |
| Maximum dose | 420 mg every 2 weeks | If needed |
| Dose changes | 2 increases | As tolerated |
Vytorin vs. Repatha Indications
Vytorin
Vytorin is approved to lower LDL cholesterol, total cholesterol, triglycerides, and Apo B, and to raise HDL cholesterol in adults with primary hyperlipidemia. It is also approved for homozygous familial hypercholesterolemia and homozygous sitosterolemia, two rare inherited cholesterol disorders. It is not approved for use in patients with active liver disease.
Lowers LDL, total cholesterol, and triglycerides
Raises HDL cholesterol
Treats homozygous familial hypercholesterolemia
Treats homozygous sitosterolemia
Repatha
Repatha is approved to lower LDL cholesterol in adults and children 10 and older with heterozygous or homozygous familial hypercholesterolemia, used alongside diet and other cholesterol medications. It is also approved to reduce the risk of heart attack, stroke, and certain heart procedures in adults with established cardiovascular disease. It is not approved for isolated high triglycerides or for children under 10.
Lowers LDL in familial hypercholesterolemia
Reduces heart attack and stroke risk
Reduces need for certain heart procedures
Approved for children 10 and older with FH
Vytorin vs. Repatha Pros and Cons
Vytorin
Vytorin is an oral combination pill with decades of clinical use and outcomes data from the IMPROVE-IT trial in people who have had a heart attack. Its statin component carries a known risk of muscle and liver side effects that requires periodic monitoring.
Pros
Convenient once-daily oral tablet, no injections
Long track record with IMPROVE-IT outcomes data
Only cholesterol drug also approved for sitosterolemia
Generic-based combination, widely stocked in pharmacies
Cons
Interacts with many common drugs via CYP3A4 pathway
Not safe for people with active liver disease
Carries muscle and rhabdomyolysis risk, especially at 80 mg
Requires periodic liver enzyme monitoring
Repatha
Repatha is a monoclonal antibody with strong cardiovascular outcomes evidence from the FOURIER trial and no boxed warning for muscle or liver toxicity. It requires an injection every two weeks or once a month rather than a daily pill, and its needle cover contains latex.
Pros
No boxed warning for muscle or liver toxicity
FOURIER trial shows reduced cardiovascular events
Approved for pediatric FH starting at age 10
Fewer drug interactions than statin-based options
Cons
Requires injection instead of a pill
Needle cover contains latex, a concern for some patients
No FDA-approved biosimilar competition to lower cost
Injection site reactions can occur
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.